Skip to main content

Advertisement

SpringerLink
Log in

After obesity drugs’ success, companies rush to preserve skeletal muscle

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This article has been updated

A growing number of companies are testing muscle-building agents to counter the side effects of dramatic weight loss and potentially to preserve lean muscle into old age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 08 March 2024

    Since the publication of this article, BioAge pivoted from launching a phase 2 trial testing azelaprag for muscle loss. Text in the print, HTML and PDF versions of the article has been removed to reflect this.

Author information

Authors and Affiliations

  1. Richmond, VA, USA

    Carrie Arnold

Authors
  1. Carrie Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arnold, C. After obesity drugs’ success, companies rush to preserve skeletal muscle. Nat Biotechnol 42, 351–353 (2024). https://doi.org/10.1038/s41587-024-02176-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-024-02176-5

  • Springer Nature America, Inc.

Search

Navigation